15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $727M | -$108M | 43.2% | -15.9% | -$22M | $342M | $160M |
| 2024 | $661M | -$79M | 43.9% | -13.9% | -$34M | $541M | $367M |
| 2023 | $592M | -$88M | 41.3% | -18.2% | -$31M | $538M | $342M |
| 2022 | $510M | -$144M | 36.9% | -30.9% | -$97M | — | $263M |
| 2021 | $484M | -$8M | 38.6% | -24.5% | -$91M | — | $317M |
| 2020 | $444M | $4M | 41.8% | -3.1% | -$28M | — | $229M |
| 2019 | $409M | $8M | 48.1% | 3.2% | $3M | — | $173M |
| 2018 | $277M | $3M | 46.0% | 3.6% | $30M | $102M | $10M |
| 2017 | $240M | -$396000 | 42.4% | 1.2% | $4M | $97M | $13M |
| 2016 | $232M | -$6M | 42.3% | 0.9% | — | $98M | $13M |
| 2015 | — | -$3M | — | — | — | $55M | $23M |
| 2014 | — | $1M | — | — | — | — | $34M |
| 2013 | — | $2M | — | — | $216000 | — | $5M |
| 2012 | — | $65000 | — | — | -$3M | — | $2M |
| 2011 | — | -$1M | — | — | -$828000 | — | $3M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $187M | -$17M | 43.3% | -9.8% | -$13M | — | $146M |
| Dec '25 | $190M | -$10M | 43.8% | -7.1% | -$7M | $342M | $160M |
| Sep '25 | $188M | -$27M | 42.8% | -14.4% | $570000 | — | $164M |
| Jun '25 | $181M | -$45M | 42.6% | -26.3% | $14M | — | $155M |
| Mar '25 | $168M | -$26M | 43.6% | -16.6% | -$30M | — | $346M |
| Dec '24 | $172M | -$15M | 44.9% | -10.7% | -$2M | $541M | $367M |
| Sep '24 | $168M | -$18M | 44.6% | -12.6% | -$2M | — | $362M |
| Jun '24 | $165M | -$19M | 44.1% | -13.3% | $814000 | — | $355M |
| Mar '24 | $156M | -$27M | 41.9% | -19.6% | -$32M | — | $332M |
| Dec '23 | $156M | -$14M | 43.5% | -11.9% | $11M | $538M | $342M |
| Sep '23 | $152M | -$19M | 41.0% | -15.9% | -$10M | — | $306M |
| Jun '23 | $147M | -$24M | 40.8% | -20.3% | -$9M | — | $289M |
| Mar '23 | $137M | -$31M | 39.9% | -25.6% | -$23M | — | $276M |
| Dec '22 | $139M | -$23M | 41.0% | -19.0% | -$8M | — | $263M |
| Sep '22 | $129M | -$37M | 38.0% | -30.7% | -$24M | — | $266M |
| Jun '22 | $125M | -$35M | 35.1% | -31.7% | -$27M | — | $284M |
| Mar '22 | $117M | -$49M | 32.6% | -44.4% | -$37M | — | $306M |
| Dec '21 | $126M | -$42M | 36.0% | -33.1% | -$32M | — | $317M |
| Sep '21 | $121M | -$20M | 38.9% | -32.7% | -$23M | — | $341M |
| Jun '21 | $122M | $76M | 43.5% | -18.4% | -$23M | — | $369M |
How the market has priced NEO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Neogenomics Inc's revenue has grown 10.4% per year. These are computed facts, not advice.
As of FY2025, Neogenomics Inc reported $342M of total debt against $160M of cash; operating income covered interest expense -30.9×.
In FY2025, gross margin was 43.2%, operating margin -15.9%, and net margin -14.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.